Gamma-hydroxybutyric acid (GHB) is a short-chain fatty acid that can potentially provide safe, prolonged sedation with minimal cardiorespiratory effects. This preliminary trial, performed in 10 three-week-old male Holstein-Friesian calves, investigated the effects of GHB administered intravenously over 5 min at a dose of 100 (G100, n=2), 150 (G150, n=4) or 200 mg/kg (G200, n=4). Once lateral recumbency was achieved, scores for sedation depth (range: 0 = no sedation to 3 = marked) and response to noxious stimulation (range: 0 = strong to 3 = absent), heart rate (HR), respiratory rate (RR), mean arterial pressure (MAP) and arterial blood gases were monitored every 15 min until sternal recumbency. Times from end of administration to lateral recumbency and return to sternal/standing positions were recorded. Dose G100 resulted in mild sedation and ataxia without decubitus. Doses G150 and G200 respectively resulted in time to lateral recumbency 8 ± 2 and 9 ± 3 min, lasting 189 ± 41 and 283 ± 29 min, while overall median (range) scores for sedation were 3 (1−3) and 3 (2−3) respectively and response to noxious stimulation 0 (0−3) and 0 (0−3) respectively. The mean ± SD for HR was 110 ± 10 and 106 ± 11 bpm respectively; for MAP 87±9 and 94±5 mmHg respectively; and for RR 28 ± 5 and 26 ± 5 bpm respectively. The mean ± SD for arterial partial pressure of oxygen (PaO2) at these two dose rates was 74 ± 6 and 74 ± 2 mmHg respectively, while the arterial partial pressure of carbon dioxide oxygen (PaCO2) was 53 ± 3 and 47 ± 0.8 mmHg respectively. Based on these preliminary results we conclude that GHB has the potential to be used as a long-acting sedative in calves. Further studies are needed to confirm this.
Salmonellosis, a zoonotic gastrointestinal disease, presents a significant global health burden with a high incidence rate. Transmission primarily occurs through the consumption of contaminated poultry products, although water and contact with asymptomatic animals are also vectors. The disease’s pervasiveness has prompted international health organizations to advocate for robust prevention and control strategies. This study focuses on the in-silico design of a multi-epitope vaccine targeting Salmonella enterica serovar Typhimurium’s fimH protein, a fimbriae component crucial for bacterial adhesion and pathogenicity. The vaccine construct was developed by identifying and synthesizing non-allergenic, antigenic, and non-toxic epitopes for both Cytotoxic T Lymphocytes and Helper T Lymphocytes. Adjuvants were incorporated to enhance immunogenicity, and the vaccine’s structure was modeled using advanced bioinformatics tools. The proposed vaccine demonstrated promising antigenicity and immunogenicity profiles, with a favorable physical-chemical property analysis. The vaccine’s structures, designed by computational analysis, suggests high likelihood to native protein configurations. Antigenicity and allergenicity assessments validate the vaccine’s immunogenic potential and hypoallergenic nature. Physicochemical evaluations indicate favorable stability and solubility profiles, essential for vaccine efficacy. This comprehensive approach to vaccine design expressed in Chlorella vulgaris holds promises for effective salmonellosis control. The multi-epitope vaccine, designed through meticulous in-silico methods, emerges as a promising candidate for controlling salmonellosis. Its strategic construction based on the fimH protein epitopes offers a targeted approach to elicit a robust immune response, potentially curbing the spread of this disease in poultry.